Prasugrel is effective and safe for neurointerventional procedures

Journal of NeuroInterventional Surgery

Volumn 5, Issue 4, 2013, Pages 332-336

  Stetler, William R ^a   Chaudhary, Neeraj ^b   Thompson, Byron Gregory ^a   Gemmete, Joseph J ^b   Maher, Cormac O ^a   Pandey, Aditya S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450; PRASUGREL; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; CARDIOVASCULAR PROCEDURE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; COHORT STUDIES; ENDOVASCULAR PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RETROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME;

EID: 84879329281     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2012-010302     Document Type: Article

References (34)

1. Guglielmi G, Vinuela F, Dion J, et al. Electrothrombosis of saccular aneurysms via endovascular approach. Part 2: preliminary clinical experience. J Neurosurg 1991;75:8-14.
2. Jabbour P, Koebbe C, Veznedaroglu E, et al. Stent-assisted coil placement for unruptured cerebral aneurysms. Neurosurg Focus 2004;17:E10.
3. Forbes TL. Preliminary results of carotid revascularization endarterectomy vs stenting trial (CREST). J Vasc Surg 2010;51:1300-1301.
4. Pyysalo LM, Keski-Nisula LH, Niskakangas TT, et al. Long-term MRI findings of patients with embolized cerebral aneurysms. Acta Radiol 2011;52:204-210.
5. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-739.
6. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832.
7. Kang HS, Han MH, Kwon BJ, et al. Is clopidogrel premedication useful to reduce thromboembolic events during coil embolization for unruptured intracranial aneurysms? Neurosurgery 2010;67:1371-1376.
8. Fiehler J, Ries T. Prevention and treatment of thromboembolism during endovascular aneurysm therapy. Klin Neuroradiol 2009;19:73-81.
9. Yamada NK, Cross DT 3rd, Pilgram TK, et al. Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms. AJNR Am J Neuroradiol 2007;28:1778-1782.
10. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403.
11. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944.
13. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-2247.
14. Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008;64:589-597.
15. Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf 2012;35:127-139.
16. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
17. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-857.
18. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-997.
19. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-484.
20. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-336.
21. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:166.
22. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high onclopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-410.
23. Angiolillo DJ, Saucedo JF, Deraad R, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010;56:1017-1023.
24. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 2007;12:205-212.
25. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-2932.
26. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482-488.
27. Jakubowski JA, Li YG, Small DS, et al. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 2010;56:29-37.
28. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009;157:562.e1-e9.
29. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762.
30. Ko YG, Suh JW, Kim BH, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383-390.
31. Price MJ, Barker CM. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists. Biomark Med 2011;5:43-51.
32. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-2560.
33. Badruddin A, Gorelick PB. Antiplatelet therapy for prevention of recurrent stroke. Curr Treat Options Neurol 2009;11:452-459.
34. Lazar LD, Lincoff AM. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Cleve Clin J Med 2009;76:707-714.